# Digifluidic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digifluidic

- Industry: Medical Devices & Equipment
- Headquarters: Zhuhai, China
- Website: www.digifluidic.com
- Total disclosed funding: $7.2M
- Latest round: Series A (Sep 10, 2022)
- Investors on record: 3

## About

Based in Zhuhai, China, and established in 2018, Digifluidic is a biotechnology company that focuses on the R&D of in vitro diagnostic (IVD) equipment. The company cooperated with the University of Macau. The company's chief scientist officer, Peiran Mai, is a professor in the Department of Electrical and Computer Engineering at the Faculty of Science and Technology of the University of Macau and the current director of the State Key Laboratory of Analog and Mixed-Signal VLSI. In December 2024, it closed a venture funding.

The company’s main business is developing in vitro diagnostic products. The company’s self-developed products mainly include nucleic acid automatic analysis systems based on digital microfluidics technology. Its products are used in the fields of medical disease diagnosis, animal and plant disease detection, health index testing, import and export inspection and quarantine, and food safety testing.

The company generates revenue by providing its self-developed in - vitro diagnostic products and related services to customers in the medical, agricultural, and food safety industries.

## Funding rounds

- Series A, Sep 10, 2022, $7.2M — Jinkong Fund Management, Wuhan Easydiagnosis Biomedicine Co., Ltd., Fun Way Capital

## Investors

- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series A
- Wuhan Easydiagnosis Biomedicine Co., Ltd. — Series A
- Fun Way Capital — Series A